Author Archives: Mary Chapman

Epidiolex Now Available in the US as a Non-controlled Substance

In a move that will give Dravet syndrome patients easier treatment access, the U.S. Drug Enforcement Administration (DEA) has reclassified Epidiolex (formerly GWP42003-P) as a non-controlled substance. In what the agency called a “descheduling,” the action removes all federally controlled-substance restrictions for the oral cannabidiol (CBD) solution that…

Patients, Supporters Worldwide Recognizing Rare Disease Day 2020

An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…

NeuroCycle Gets $500K NINDS Grant to Study Dravet Therapies

The National Institute of Neurological Disorders and Stroke (NINDS) has awarded NeuroCycle Therapeutics a $500,000 grant to test advanced subtype-selective GBAA receptor modulators in Dravet syndrome models. The Small Business Innovation Research grant to evaluate NCT10004 and NCT10015 furthers the pharmaceutical company’s efforts…

Epilepsy Foundation Awards $300K in Grants for New Treatments

With the goal of advancing development of new treatments for patients living with poorly controlled seizures, the Epilepsy Foundation has awarded $300,000 in grants to two leading researchers. The grants will go to Matthew Gentry, PhD, a professor at the University of Kentucky, and Greg Worrell, MD, PhD,…